| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03082014 Details | 2023-03-09 Interventional | 3 | 101 | Amlodipine Atenolol Losartan Cerebral Small … | completed for the primary study group of sporadic SVD patients, halted prematurely for the
additional study group due to slow recruitment at 26 of 30 CADASIL patients in December 2022 - | |||
| NCT03435640 2018-004625-84 Details | 2023-03-08 Interventional | 1/2 | 64 | Nivolumab Carcinoma Carcinoma, Merk… Carcinoma, Rena… Squamous Cell C… Triple Negative… Colorectal Canc… Head and Neck S… Melanoma Merkel Cell Car… Renal Cell Carc… Sarcoma Triple Negative… | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the
study. The decision was not due to safety reasons. - | |||
| NCT03080935 2016-004066-26 Details | 2023-03-08 Interventional | 3 | 1600 | Evolocumab Cardiovascular … Dyslipidemias Dyslipidemia | Amgen business decision to close study early This study was terminated to coincide with the completion of study 20130295 (NCT02867813). The study was not terminated due to any safety findings. | |||
| NCT03775421 2018-002821-45 Details | 2023-03-07 Interventional | 3 | 112 | Macitentan Heart Defects, … Heart Diseases Congenital Hear… | As The RUBATO DB study (NCT03153137) did not show any benefit of treatment with macitentan in
Fontan-palliated participants, the sponsor has decided to terminate the RUBATO OL study
(NCT03775421). No new safety observations were made. The study was stopped prematurely by the sponsor because the main double-blind (DB) study (AC-055H301; NCT03153137) did not meet the primary and secondary efficacy outcome measures. | |||
| NCT03015792 Details | 2023-03-07 Interventional | 1/2 | 18 | BB 1101 Dexamethasone Dexamethasone a… Ibrutinib Ichthammol Lenalidomide Multiple Myelom… Neoplasms, Plas… Recurrent Plasm… Refractory Plas… | Per CS0139535 -submitter stated we can update status to Admin complete- low accrual reasoning - | |||
| NCT05039944 Details | 2023-03-06 Interventional | 2 | 7 | Irinotecan Colorectal Neop… Colorectal Canc… | Company research strategy adjustment - | |||
| NCT04992273 NCT05149300 2021-004590-30 Details | 2023-03-06 Interventional | 2 | 7 | Casirivimab and… COVID-19 | Emerging SARS-CoV-2 variants impacting susceptibility to study drug The study was terminated early due to emerging SARS-CoV-2 variants impacting susceptibility to the study drug. The early termination was not due to safety findings. | |||
| NCT04895410 2021-001067-24 Details | 2023-03-06 Interventional | 1 | 8 | Daratumumab Dexamethasone Pomalidomide Multiple Myelom… Neoplasms, Plas… | Strategic considerations - | |||
| NCT04379518 Details | 2023-03-06 Interventional | 1/2 | - | Interferon alph… Interferon-alph… Interferons poly(I).poly(c1… COVID-19 Laboratory Infe… Neoplasms Hematopoietic a… Malignant Solid… Symptomatic COV… | working on revision to protocol - | |||
| NCT03996473 2018-003704-39 Details | 2023-03-06 Interventional | 1 | 7 | Pembrolizumab Radium Ra 223 d… Carcinoma, Non-… | LPLV reached on 30Jan2023. Study was closed early for feasibility reasons related to enrollment
of first line IO naïve patients. Safety data is consistent with the known safety profile of
both drugs and no new safety issues have been observed - | |||
| NCT04236141 Details | 2023-03-03 Interventional | 3 | 42 | Bendamustine Hy… Polatuzumab ved… Rituximab Lymphoma Lymphoma, Large… Diffuse, Large … | Sponsor's decision, no safety concerns - | |||
| NCT02452268 Details | 2023-03-03 Interventional | 1 | 83 | Spartalizumab Neoplasm Metast… Metastatic and … | business decision - | |||
| NCT02255305 Details | 2023-03-03 Interventional | 2 | 6 | Anti-Bacterial … Anti-Infective … Clostridium Inf… Infections Clostridium Dif… | Due to personnel issues for finding and enrolling patients, performing appropriate follow-up
and performing FMT procedure Study ended early due to personnel needed for study completion (enrollment, follow-up, FMT procedure) and did not reach enrollment goals. | |||
| NCT05048940 Details | 2023-03-02 Interventional | 3 | 0 | Vaccines COVID-19 Covid19 | The health authority indicates that the official vaccination schedule differs from that
described in the protocol. - | |||
| NCT04748848 2020-005341-16 Details | 2023-03-02 Interventional | 1 | 1 | Azacitidine Pulrodemstat be… Venetoclax Leukemia Leukemia, Myelo… Leukemia, Myelo… | Business objectives have changed. - | |||
| NCT04675983 Details | 2023-03-02 Interventional | 3 | 36 | Capecitabine Fluorouracil Oxaliplatin Ramucirumab Adenocarcinoma Gastric Adenoca… | Due to the company's development strategy adjustment, Innovent Biologics has decided not to
continue this study after consultation with investigators - | |||
| NCT04650490 Details | 2023-03-02 Interventional | 2 | 0 | Immunomodulatin… Brain Neoplasms Carcinoma, Non-… Lung Neoplasms Neoplasm Metast… Brain Metastase… Non Small Cell … | failure to enroll - | |||
| NCT03838848 Details | 2023-03-02 Interventional | 2 | 120 | Antibodies Carboplatin Immunoglobulins Pemetrexed Carcinoma, Non-… Lung Neoplasms Stage IV Non-sm… | Cohort A,B,C end enrollments. Cohort D and E were considered to have no significant clinical
benefit at the SMC meeting and decided to terminate enrollment. - | |||
| NCT05545319 2022-002447-22 Details | 2023-03-01 Interventional | 2 | 0 | Nirmatrelvir Ritonavir COVID-19 Coronavirus Inf… Severe Acute Re… Child, Hospital… Coronavirus Dis… Hospitalization Immunocompromis… Severe Acute Re… | Termination due to challenges related to the operational feasibility of the study, taking into
account the current epidemiology and declining hospitalization rates for severe COVID-19. - | |||
| NCT04328285 2020-001188-96 Details | 2023-03-01 Interventional | 3 | 118 | Hydroxychloroqu… Lopinavir Ritonavir COVID-19 | French authority's decision - |